Myocardial InfarctionDIFOCCULT-2NCT05705102
Time for a Paradigm Shift: STEMI/NSTEMI to OMI/NOMI ?
An observational study of Myocardial Infarction and Myocardial Ischemia, run by Marmara University at 1 site in Turkey (Türkiye).
Trial summary
The current ST-segment elevation (STEMI)/non-STEMI treatment paradigm misses nearly one fourth of acute coronary occlusions (ACO) that needs immediately reperfusion. Many of these cases can be recognized by subtle changes on ECG, but the current STEMI criteria do not include them. Read more about this study
- Who is it for?
- Ages 18 to 90 years
- Conditions the study is for
- Myocardial Infarction, Myocardial Ischemia
- What is being tested?
- Coronary intervention
- How many people
- 2,500 participants
- Where
- 1 siteTurkey (Türkiye)
- Study dates
- 1 Sep 2020to 1 Aug 2024
- How long will I take part?
- 1 Year
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 90 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The adult patients who are admitted to the emergency department with a clinical picture compatible with acute coronary syndrome.
Who may be able to join
- Clinical picture compatible with acute coronary syndrome AND recognized as OMI/STEMI (according to the treating provider) or cardiac high-sensitive troponins levels are elevated
Who cannot join
- Unable to acquire ECG
Trial locations and contacts
1 site in 1 country.
Turkey (Türkiye)1 site
Marmara University Pendik Training and Research Hospital
Istanbul
About this study
Official title: Time for a DIagnostic Paradigm Shift From ST-elevation/Non-ST-elevation to OCClUsion/Non-occLusion Myocardial infarcTion?
The current ST-segment elevation (STEMI)/non-STEMI treatment paradigm misses nearly one fourth of acute coronary occlusions (ACO) that needs immediately reperfusion. Many of these cases can be recognized by subtle changes on ECG, but the current STEMI criteria do not include them. The investigators of this research believe a new occlusive/non-occlusive myocardial infarction (OMI/NOMI) approach will be superior to the established STEMI/non-STEMI paradigm in early detection of ACO, limiting infarct size, reducing re-hospitalizations and most important of all, reducing mortality.
Read the detailed description
The patients with acute coronary occlusion (ACO) or potentially imminent occlusion, with insufficient collateral circulation, have myocardium that is at risk of infarction unless they undergo immediate reperfusion via thrombolytics or percutaneous coronary intervention (PCI). One of the most important tasks in emergency cardiology is to immediately identify acute coronary occlusion (ACO) myocardial infarction (OMI) among all patients who present with symptoms compatible with acute myocardial infarction (MI), and distinguish them from those without MI, and from those with MI that does not have ongoing myocyte loss (Non-OMI, or NOMI) who can be managed with medical therapy and for whom potentially harmful invasive interventions can be deferred. The electrocardiogram (ECG) plays a central role in this process.
The presence or absence of ST-segment elevation (STE) is principally used to define patients who need emergent coronary revascularization, since subgroup analyses of the Fibrinolytic Therapy Trialists' (FTT) meta-analysis indicated that patients with STE on ECG gain a slightly better survival benefit from emergent reperfusion. After fine-tuning of STE cutoffs used in this analysis, universally agreed STEMI criteria became the current guideline-supported ECG paradigm.
However, the evidence accumulated in the past 20 years indicate that there is still room for substantial improvement. Although patients with ACO are the group that is believed to benefit from emergent reperfusion therapy, fibrinolytic studies did not investigate the presence or absence of ACO among enrolled patients. Moreover, they did not specifically focus on ECG findings, including STE; four of the nine trials even did not use ECG for enrollment, and the remaining five defined their version of STE with varying cutoffs, and without specified measurement methods. To reconcile different STE criteria used in various studies, several investigators compared STE in normal subjects and patients with MI. However, none of the studies cited in the current universal definition of MI used ACO on angiography as an endpoint, so these criteria were actually not designed to differentiate STEMI from non-STEMI.
In the past 20 years, several investigators, including this group, have demonstrated that factors other than STE, including STE of magnitude less than those recommended by the guidelines (but in combination with other features), can help in diagnosing ACO or excluding it. Proportionality, which is unfortunately completely absent in the STEMI criteria, is a common factor in most of these studies: proportionality is the idea that any amount of STE or ST-segment depression (STD), or T-wave size, must be assessed relative to the QRS amplitude. Many other clues should also be taken into account when differentiating STE due to ACO from other causes of STE, which has been described in detail in recent reviews published by our group.
Studies show current STEMI criteria miss nearly one-third of ACO with the result that this unfortunate group of patients, labeled as non-STEMI, are deprived of emergent reperfusion therapy. Many studies showed that approximately one third to one-fifth of the patients with ACO had equal to or less than 1 mm of STE, hyperacute T-waves, non-contiguous STE patterns, etc. These patients are unfortunately deprived of emergent reperfusion therapy and ACO is only found after rising troponin level identifies them as having MI and they undergo a next-day angiogram. Furthermore, this proportion may be underestimated, since a large percentage of total thrombotic occlusions spontaneously reperfuse by this time; unfortunately, only after a substantial loss of myocardium. These findings are highly relevant and important, as those with unrecognized ACO had higher short and long-term risk of mortality.
Recently, the DIagnostic accuracy oF electrocardiogram for acute coronary OCClUsion resuLTing in myocardial infarction (DIFOCCULT) study [1], compared OMI/non-OMI approach with STEMI/non-STEMI paradigm. This is the largest study specifically designed to question the STEMI/non-STEMI paradigm, in which a set of predefined ECG findings in addition to STEMI criteria were used, and the final outcome was a composite ACO endpoint. In accordance with the previous observations, over one-fourth of the patients initially classified as having non-STEMI were re-classified by the ECG reviewers, blinded to all outcome data, as having OMI. This subgroup had a higher frequency of ACO, myocardial damage, and both in-hospital and long-term mortality compared to the non-OMI group. The OMI/non-OMI approach to the ECG had a superior diagnostic accuracy compared to the STE/non-STEMI approach in the prediction of both ACO and long-term mortality.
Similarly, another retrospective case-control study [2] of 808 patients with suspected acute coronary syndrome (ACS) symptoms compared the accuracy of STEMI criteria vs. structured expert ECG interpretation which incorporates other findings of OMI including hyper-acute T-waves, STD of posterior OMI, STE less than the STEMI criteria cutoffs, etc. STEMI (-) OMI patients had similar infarct size measured by peak troponin but greater delays to angiography compared with the STEMI (+) OMI patients. Of the 808 patients, 49% had MI (33% OMI; 16% NOMI). Sensitivity, specificity, and accuracy of STEMI criteria vs Expert 1 for OMI among all 808 patients were 41% vs 86%, 94% vs 91%, and 77% vs 89%, and for Expert 2 among 250 patients were 36% vs 80%, 91% vs 92%, and 76% vs 89%. OMIs were correctly diagnosed a median of 1.5 hours (mean 3.0 hours) earlier by structured expert ECG interpretation than by STEMI criteria, or by angiogram if the ECG never met STEMI criteria.
Lastly, the STEMI/NSTEMI vs. OMI/NOMI paradigm were compared in 467 consecutive high/risk acute coronary syndrome patients [3]. Among the 108 patients with OMI, only 60% had any ECG meeting STEMI criteria. STEMI (-) OMI patients had similar peak troponins, wall motion abnormalities, left ventricular ejection fraction (LVEF) and clinical outcomes as compared with the STEMI (+) OMI patients, but were much less likely to receive emergent catheterization.
These data support the notion that the STEMI (-) but OMI (+) patients likely represent a missed opportunity under the STEMI/NSTEMI paradigm. A new OMI/NOMI approach has the potential of being the next significant improvement in modern MI care.
The hypothesis of this study is that the new OMI/NOMI approach will be superior to the established STEMI/NSTEMI paradigm in early detection of ACO, limiting infarct size, reducing rehospitalizations and most important of all, reducing mortality.
The adult patients (age >18 years) who are admitted to the emergency department with a clinical picture compatible with acute coronary syndrome will be screened for enrollment into the study. If any ECG in the emergency department is recognized as OMI/STEMI (according to the treating provider) or if the troponins are elevated, the patient will be enrolled into the study.
Before the study a detailed briefing will be done to the interventional cardiologists who will form the intervention groups.
Although the STEMI/NSTEMI approach is the current norm (a diagnosis of STEMI requires emergent catheterization, whereas the patients with NSTEMI are stabilized first and then electively undergo catheterization unless there are high-risk features), it would be unethical for a ECG reviewer, who is trained in recognizing the signs of ACO not fulfilling the current STEMI criteria, to suspend emergent reperfusion therapy after an OMI diagnosis has been made. Therefore, the ECG interpreters who are trained in OMI diagnosis cannot be randomized to STEMI/NSTEMI versus OMI/NOMI approaches. Hence, the groups will be randomized in the following fashion: A OMI/NOMI and a STEMI/NSTEMI intervention group will be formed. Intervention group 1 will be encouraged to use OMI/NOMI approach in patients with suspected acute coronary syndrome, and group 2 will use the current STEMI/NSTEMI approach.
The ECG interpreters (who contact the patient first and decide the treatment style, according to the center this can be either an emergency physician or a cardiologist) in both groups will be ensured to have a similar experience in terms of years of training. The ECG interpreter will thus elect to go for catheterization based on his/her ECG approach and, whether that is by OMI or STEMI paradigm, the patient will be enrolled accordingly and the reason for proceeding to the catheterization laboratory will be written on the study form. The interventional cardiologists in both groups will be ensured to have a similar experience level (in terms of years of training, and angiography and primary PCI counts in the past year). In the STEMI/NSTEMI arm, the contributors will blindly continue their practice, the ECG interpretation and decision to activate the catheterization laboratory will be done as usual. In the OMI/NOMI arm, an intensive course on ECG diagnosis of OMI using previously published algorithms and ECGs will be provided [4, 5]. After these two groups are formed, the patients will be block-randomized into STEMI/NSTEMI and OMI/NOMI cohorts according to the team on-duty. No intervention to the decisions will be done during the study process.
The STEMI/NSTEMI group will use the following criteria for the diagnosis of STEMI: (1) New ST-segment elevation at the J-point in two contiguous leads with the cut-point: ≥ 1 mm in all leads other than leads V2-V3 where the following cut-points apply: ≥2 mm in men ≥40 years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age, and (2) a peak troponin level above 99th percentile and (3) a clinical picture compatible with acute coronary syndrome. If the decision to proceed to the cath lab was done only with the first criterion, the participant will remain in the study, even if the second criterion is not met. The patients meeting only criteria (2) and (3) will be classified as NSTEMI.
In the OMI/NOMI group, the algorithm defined in the DIFOCCULT trial [1, 4, 5] will be used for ECG diagnosis (1). Additionally (2) a peak troponin level above 99th percentile and (3) a clinical picture compatible with acute coronary syndrome will be required. If the decision to proceed emergently to the cath lab was done only with the first criterion, the participant will remain in the study, even if the second criterion is not met. The patients who do not meet ECG-OMI criteria will be classified as NOMI, if: (1) a peak troponin level above 99th percentile and (2) a clinical picture compatible with acute coronary syndrome is present.
STEMI and OMI patients (will be taken as STEMI equivalents) will be managed according to the current STEMI guidelines, whereas NSTEMI and NOMI patients are managed according to the current NSTEMI guidelines. A separate diagnostic group with 'probable OMI' and 'high-risk STEMI' is also allowed for patients who do not fulfil STEMI/OMI criteria but need urgent catheterization for other high-risk features or high clinical suspicion for having an ACO. These patients will also be managed according to the current guidelines. However, patients will be excluded from analysis if their early catheterization is based solely on social or logistical considerations, and not based on the medical need. For example, a patient would be excluded if he/she is brought to the cath lab early based on the immediate availability of cath lab or because the patient is already scheduled for elective coronary angiography.
No other intervention will be done during study. After the patient enrollment period, data will be retrieved from the system and will be compared.
- Conditions
- Myocardial Infarction, Myocardial Ischemia
- Being tested
- Coronary intervention
- Keywords
- acute coronary occlusion, electrocardiography, myocardial infarction, ST-segment elevation
- Medical subject headings
- Myocardial Infarction, Myocardial Ischemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary interventionOther
Coronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for <24h.
| Study group | Role | What they receive |
|---|---|---|
| OMI/NOMI group | In this group, the patients will be managed according to OMI/NOMI paradigm. OMI patients, even without STEMI criteria, will be taken immediately to the cath lab. Receives: Other: Coronary intervention | |
| STEMI/NSTEMI group | Standard care Receives: Other: Coronary intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mortality
Mortality
Measured: One year
Mortality in OMI (+) but STEMI (-) patients
Mortality in OMI (+) but STEMI (-) patients
Measured: One year
Secondary outcomes (3)
ACO
Acute coronary occlusion on angiogram
Measured: At index hospitalization (<7 day)
Infarct size
Infarct size by 72-hour peak troponin level
Measured: At index hospitalization (<7 day)
Left ventricular function
Left ventricular function by echocardiography
Measured: At index hospitalization (<7 day)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Jan 2023
- Study start1 Sep 2020
- Primary completion1 Sep 2022
- Study completion1 Aug 2024
Why it stopped: Problems due to retrospective data acquisition
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (5)Papers the sponsor has linked to this study.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Prospective
- Enrolment
- 2,500 participants (actual)
- Target duration
- 1 Year
Sponsor and investigators
- Lead sponsor
- Marmara University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Emre Aslanger, Marmara University
- Investigators
- Emre Aslanger, Principal investigator, Marmara University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05705102
- Sponsor's protocol ID
- MarmaraCard002
- Acronym
- DIFOCCULT-2
- Status last verified
- Aug 2024
- First submitted
- 21 Jan 2023
- Last updated
- 27 Aug 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Aslanger EK, Yildirimturk O, Simsek B, Bozbeyoglu E, Simsek MA, Yucel Karabay C, Smith SW, Degertekin M. DIagnostic accuracy oF electrocardiogram for acute coronary OCClUsion resuLTing in myocardial infarction (DIFOCCULT Study). Int J Cardiol Heart Vasc. 2020 Jul 30;30:100603. doi: 10.1016/j.ijcha.2020.100603. eCollection 2020 Oct.
PubMed 32775606Pendell Meyers H, Bracey A, Lee D, Lichtenheld A, Li WJ, Singer DD, Rollins Z, Kane JA, Dodd KW, Meyers KE, Shroff GR, Singer AJ, Smith SW. Accuracy of OMI ECG findings versus STEMI criteria for diagnosis of acute coronary occlusion myocardial infarction. Int J Cardiol Heart Vasc. 2021 Apr 12;33:100767. doi: 10.1016/j.ijcha.2021.100767. eCollection 2021 Apr.
PubMed 33912650Meyers HP, Bracey A, Lee D, Lichtenheld A, Li WJ, Singer DD, Kane JA, Dodd KW, Meyers KE, Thode HC, Shroff GR, Singer AJ, Smith SW. Comparison of the ST-Elevation Myocardial Infarction (STEMI) vs. NSTEMI and Occlusion MI (OMI) vs. NOMI Paradigms of Acute MI. J Emerg Med. 2021 Mar;60(3):273-284. doi: 10.1016/j.jemermed.2020.10.026. Epub 2020 Dec 9.
PubMed 33308915Aslanger EK, Meyers PH, Smith SW. STEMI: A transitional fossil in MI classification? J Electrocardiol. 2021 Mar-Apr;65:163-169. doi: 10.1016/j.jelectrocard.2021.02.001. Epub 2021 Feb 13.
PubMed 33640636Aslanger EK, Meyers HP, Smith SW. Recognizing electrocardiographically subtle occlusion myocardial infarction and differentiating it from mimics: Ten steps to or away from cath lab. Turk Kardiyol Dern Ars. 2021 Sep;49(6):488-500. doi: 10.5543/tkda.2021.21026.
PubMed 34523597
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Time for a DIagnostic Paradigm Shift From ST-elevation/Non-ST-elevation to OCClUsion/Non-occLusion Myocardial infarcTion?
- ClinicalTrials.gov ID
- NCT05705102
- Acronym / sponsor ID
- DIFOCCULT-2 / MarmaraCard002
- Conditions
- Myocardial Infarction, Myocardial Ischemia
- Keywords
- acute coronary occlusion, electrocardiography, myocardial infarction, ST-segment elevation
- Study type
- Observational
- Recruitment status
- TerminatedReason stopped: Problems due to retrospective data acquisition
- Enrolment
- 2,500 participants (actual)
- Lead sponsor
- Marmara UniversityUniversity, hospital or other
- Study start
- 1 Sep 2020 (actual)
- Primary completion
- 1 Sep 2022 (actual)
- Study completion
- 1 Aug 2024 (actual)
- First posted
- 30 Jan 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The current ST-segment elevation (STEMI)/non-STEMI treatment paradigm misses nearly one fourth of acute coronary occlusions (ACO) that needs immediately reperfusion. Many of these cases can be recognized by subtle changes on ECG, but the current STEMI criteria do not include them. The investigators of this research believe a new occlusive/non-occlusive myocardial infarction (OMI/NOMI) approach will be superior to the established STEMI/non-STEMI paradigm in early detection of ACO, limiting infarct size, reducing re-hospitalizations and most important of all, reducing mortality.
Detailed description
The patients with acute coronary occlusion (ACO) or potentially imminent occlusion, with insufficient collateral circulation, have myocardium that is at risk of infarction unless they undergo immediate reperfusion via thrombolytics or percutaneous coronary intervention (PCI). One of the most important tasks in emergency cardiology is to immediately identify acute coronary occlusion (ACO) myocardial infarction (OMI) among all patients who present with symptoms compatible with acute myocardial infarction (MI), and distinguish them from those without MI, and from those with MI that does not have ongoing myocyte loss (Non-OMI, or NOMI) who can be managed with medical therapy and for whom potentially harmful invasive interventions can be deferred. The electrocardiogram (ECG) plays a central role in this process.
The presence or absence of ST-segment elevation (STE) is principally used to define patients who need emergent coronary revascularization, since subgroup analyses of the Fibrinolytic Therapy Trialists' (FTT) meta-analysis indicated that patients with STE on ECG gain a slightly better survival benefit from emergent reperfusion. After fine-tuning of STE cutoffs used in this analysis, universally agreed STEMI criteria became the current guideline-supported ECG paradigm.
However, the evidence accumulated in the past 20 years indicate that there is still room for substantial improvement. Although patients with ACO are the group that is believed to benefit from emergent reperfusion therapy, fibrinolytic studies did not investigate the presence or absence of ACO among enrolled patients. Moreover, they did not specifically focus on ECG findings, including STE; four of the nine trials even did not use ECG for enrollment, and the remaining five defined their version of STE with varying cutoffs, and without specified measurement methods. To reconcile different STE criteria used in various studies, several investigators compared STE in normal subjects and patients with MI. However, none of the studies cited in the current universal definition of MI used ACO on angiography as an endpoint, so these criteria were actually not designed to differentiate STEMI from non-STEMI.
In the past 20 years, several investigators, including this group, have demonstrated that factors other than STE, including STE of magnitude less than those recommended by the guidelines (but in combination with other features), can help in diagnosing ACO or excluding it. Proportionality, which is unfortunately completely absent in the STEMI criteria, is a common factor in most of these studies: proportionality is the idea that any amount of STE or ST-segment depression (STD), or T-wave size, must be assessed relative to the QRS amplitude. Many other clues should also be taken into account when differentiating STE due to ACO from other causes of STE, which has been described in detail in recent reviews published by our group.
Studies show current STEMI criteria miss nearly one-third of ACO with the result that this unfortunate group of patients, labeled as non-STEMI, are deprived of emergent reperfusion therapy. Many studies showed that approximately one third to one-fifth of the patients with ACO had equal to or less than 1 mm of STE, hyperacute T-waves, non-contiguous STE patterns, etc. These patients are unfortunately deprived of emergent reperfusion therapy and ACO is only found after rising troponin level identifies them as having MI and they undergo a next-day angiogram. Furthermore, this proportion may be underestimated, since a large percentage of total thrombotic occlusions spontaneously reperfuse by this time; unfortunately, only after a substantial loss of myocardium. These findings are highly relevant and important, as those with unrecognized ACO had higher short and long-term risk of mortality.
Recently, the DIagnostic accuracy oF electrocardiogram for acute coronary OCClUsion resuLTing in myocardial infarction (DIFOCCULT) study [1], compared OMI/non-OMI approach with STEMI/non-STEMI paradigm. This is the largest study specifically designed to question the STEMI/non-STEMI paradigm, in which a set of predefined ECG findings in addition to STEMI criteria were used, and the final outcome was a composite ACO endpoint. In accordance with the previous observations, over one-fourth of the patients initially classified as having non-STEMI were re-classified by the ECG reviewers, blinded to all outcome data, as having OMI. This subgroup had a higher frequency of ACO, myocardial damage, and both in-hospital and long-term mortality compared to the non-OMI group. The OMI/non-OMI approach to the ECG had a superior diagnostic accuracy compared to the STE/non-STEMI approach in the prediction of both ACO and long-term mortality.
Similarly, another retrospective case-control study [2] of 808 patients with suspected acute coronary syndrome (ACS) symptoms compared the accuracy of STEMI criteria vs. structured expert ECG interpretation which incorporates other findings of OMI including hyper-acute T-waves, STD of posterior OMI, STE less than the STEMI criteria cutoffs, etc. STEMI (-) OMI patients had similar infarct size measured by peak troponin but greater delays to angiography compared with the STEMI (+) OMI patients. Of the 808 patients, 49% had MI (33% OMI; 16% NOMI). Sensitivity, specificity, and accuracy of STEMI criteria vs Expert 1 for OMI among all 808 patients were 41% vs 86%, 94% vs 91%, and 77% vs 89%, and for Expert 2 among 250 patients were 36% vs 80%, 91% vs 92%, and 76% vs 89%. OMIs were correctly diagnosed a median of 1.5 hours (mean 3.0 hours) earlier by structured expert ECG interpretation than by STEMI criteria, or by angiogram if the ECG never met STEMI criteria.
Lastly, the STEMI/NSTEMI vs. OMI/NOMI paradigm were compared in 467 consecutive high/risk acute coronary syndrome patients [3]. Among the 108 patients with OMI, only 60% had any ECG meeting STEMI criteria. STEMI (-) OMI patients had similar peak troponins, wall motion abnormalities, left ventricular ejection fraction (LVEF) and clinical outcomes as compared with the STEMI (+) OMI patients, but were much less likely to receive emergent catheterization.
These data support the notion that the STEMI (-) but OMI (+) patients likely represent a missed opportunity under the STEMI/NSTEMI paradigm. A new OMI/NOMI approach has the potential of being the next significant improvement in modern MI care.
The hypothesis of this study is that the new OMI/NOMI approach will be superior to the established STEMI/NSTEMI paradigm in early detection of ACO, limiting infarct size, reducing rehospitalizations and most important of all, reducing mortality.
The adult patients (age >18 years) who are admitted to the emergency department with a clinical picture compatible with acute coronary syndrome will be screened for enrollment into the study. If any ECG in the emergency department is recognized as OMI/STEMI (according to the treating provider) or if the troponins are elevated, the patient will be enrolled into the study.
Before the study a detailed briefing will be done to the interventional cardiologists who will form the intervention groups.
Although the STEMI/NSTEMI approach is the current norm (a diagnosis of STEMI requires emergent catheterization, whereas the patients with NSTEMI are stabilized first and then electively undergo catheterization unless there are high-risk features), it would be unethical for a ECG reviewer, who is trained in recognizing the signs of ACO not fulfilling the current STEMI criteria, to suspend emergent reperfusion therapy after an OMI diagnosis has been made. Therefore, the ECG interpreters who are trained in OMI diagnosis cannot be randomized to STEMI/NSTEMI versus OMI/NOMI approaches. Hence, the groups will be randomized in the following fashion: A OMI/NOMI and a STEMI/NSTEMI intervention group will be formed. Intervention group 1 will be encouraged to use OMI/NOMI approach in patients with suspected acute coronary syndrome, and group 2 will use the current STEMI/NSTEMI approach.
The ECG interpreters (who contact the patient first and decide the treatment style, according to the center this can be either an emergency physician or a cardiologist) in both groups will be ensured to have a similar experience in terms of years of training. The ECG interpreter will thus elect to go for catheterization based on his/her ECG approach and, whether that is by OMI or STEMI paradigm, the patient will be enrolled accordingly and the reason for proceeding to the catheterization laboratory will be written on the study form. The interventional cardiologists in both groups will be ensured to have a similar experience level (in terms of years of training, and angiography and primary PCI counts in the past year). In the STEMI/NSTEMI arm, the contributors will blindly continue their practice, the ECG interpretation and decision to activate the catheterization laboratory will be done as usual. In the OMI/NOMI arm, an intensive course on ECG diagnosis of OMI using previously published algorithms and ECGs will be provided [4, 5]. After these two groups are formed, the patients will be block-randomized into STEMI/NSTEMI and OMI/NOMI cohorts according to the team on-duty. No intervention to the decisions will be done during the study process.
The STEMI/NSTEMI group will use the following criteria for the diagnosis of STEMI: (1) New ST-segment elevation at the J-point in two contiguous leads with the cut-point: ≥ 1 mm in all leads other than leads V2-V3 where the following cut-points apply: ≥2 mm in men ≥40 years; ≥2.5 mm in men <40 years, or ≥1.5 mm in women regardless of age, and (2) a peak troponin level above 99th percentile and (3) a clinical picture compatible with acute coronary syndrome. If the decision to proceed to the cath lab was done only with the first criterion, the participant will remain in the study, even if the second criterion is not met. The patients meeting only criteria (2) and (3) will be classified as NSTEMI.
In the OMI/NOMI group, the algorithm defined in the DIFOCCULT trial [1, 4, 5] will be used for ECG diagnosis (1). Additionally (2) a peak troponin level above 99th percentile and (3) a clinical picture compatible with acute coronary syndrome will be required. If the decision to proceed emergently to the cath lab was done only with the first criterion, the participant will remain in the study, even if the second criterion is not met. The patients who do not meet ECG-OMI criteria will be classified as NOMI, if: (1) a peak troponin level above 99th percentile and (2) a clinical picture compatible with acute coronary syndrome is present.
STEMI and OMI patients (will be taken as STEMI equivalents) will be managed according to the current STEMI guidelines, whereas NSTEMI and NOMI patients are managed according to the current NSTEMI guidelines. A separate diagnostic group with 'probable OMI' and 'high-risk STEMI' is also allowed for patients who do not fulfil STEMI/OMI criteria but need urgent catheterization for other high-risk features or high clinical suspicion for having an ACO. These patients will also be managed according to the current guidelines. However, patients will be excluded from analysis if their early catheterization is based solely on social or logistical considerations, and not based on the medical need. For example, a patient would be excluded if he/she is brought to the cath lab early based on the immediate availability of cath lab or because the patient is already scheduled for elective coronary angiography.
No other intervention will be done during study. After the patient enrollment period, data will be retrieved from the system and will be compared.
Study design
- Observational model
- Other
- Time perspective
- Prospective
- Target follow-up
- 1 Year
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| OMI/NOMI group | – | Other: Coronary interventionIn this group, the patients will be managed according to OMI/NOMI paradigm. OMI patients, even without STEMI criteria, will be taken immediately to the cath lab. |
| STEMI/NSTEMI group | – | Other: Coronary interventionStandard care |
Who may qualify
- Ages
- 18 to 90 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The adult patients who are admitted to the emergency department with a clinical picture compatible with acute coronary syndrome.
Key inclusion criteria (1 listed)
- Clinical picture compatible with acute coronary syndrome AND recognized as OMI/STEMI (according to the treating provider) or cardiac high-sensitive troponins levels are elevated
Key exclusion criteria (1 listed)
- Unable to acquire ECG
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary interventionCoronary intervention will be done immediately in patients with OMI (even STEMI criteria are negative), instead of waiting for <24h. | Other | OMI/NOMI group, STEMI/NSTEMI group |
Primary outcome
Mortality
Time frame: One year
Mortality
Mortality in OMI (+) but STEMI (-) patients
Time frame: One year
Mortality in OMI (+) but STEMI (-) patients
3 secondary outcomes
ACO
Time frame: At index hospitalization (<7 day)
Infarct size
Time frame: At index hospitalization (<7 day)
Left ventricular function
Time frame: At index hospitalization (<7 day)
Results and safety
The study was stopped early (reason given: Problems due to retrospective data acquisition). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2024.
- Background: PubMed 32775606Aslanger EK, Yildirimturk O, Simsek B, Bozbeyoglu E, Simsek MA, Yucel Karabay C, Smith SW, Degertekin M. DIagnostic accuracy oF electrocardiogram for acute coronary OCClUsion resuLTing in myocardial infarction (DIFOCCULT Study). Int J Cardiol Heart Vasc. 2020 Jul 30;30:100603. doi: 10.1016/j.ijcha.2020.100603. eCollection 2020 Oct.
- Background: PubMed 33912650Pendell Meyers H, Bracey A, Lee D, Lichtenheld A, Li WJ, Singer DD, Rollins Z, Kane JA, Dodd KW, Meyers KE, Shroff GR, Singer AJ, Smith SW. Accuracy of OMI ECG findings versus STEMI criteria for diagnosis of acute coronary occlusion myocardial infarction. Int J Cardiol Heart Vasc. 2021 Apr 12;33:100767. doi: 10.1016/j.ijcha.2021.100767. eCollection 2021 Apr.
- Background: PubMed 33308915Meyers HP, Bracey A, Lee D, Lichtenheld A, Li WJ, Singer DD, Kane JA, Dodd KW, Meyers KE, Thode HC, Shroff GR, Singer AJ, Smith SW. Comparison of the ST-Elevation Myocardial Infarction (STEMI) vs. NSTEMI and Occlusion MI (OMI) vs. NOMI Paradigms of Acute MI. J Emerg Med. 2021 Mar;60(3):273-284. doi: 10.1016/j.jemermed.2020.10.026. Epub 2020 Dec 9.
- Background: PubMed 33640636Aslanger EK, Meyers PH, Smith SW. STEMI: A transitional fossil in MI classification? J Electrocardiol. 2021 Mar-Apr;65:163-169. doi: 10.1016/j.jelectrocard.2021.02.001. Epub 2021 Feb 13.
- Background: PubMed 34523597Aslanger EK, Meyers HP, Smith SW. Recognizing electrocardiographically subtle occlusion myocardial infarction and differentiating it from mimics: Ten steps to or away from cath lab. Turk Kardiyol Dern Ars. 2021 Sep;49(6):488-500. doi: 10.5543/tkda.2021.21026.
- Individual participant dataSharing planned: Undecided
Related trials for Myocardial Infarction
RecruitingPhase 4
Efficacy and Safety of a Half-dose Bolus of r-SAK Prior to Primary PCI in ST-elevation Myocardial Infarction
ST Elevation Myocardial Infarction
Recruiting
ODSSEY-SCD_Identification Of Markers to preDict the rISk of Sudden Cardiac Death in Moderated LVEF in ischEmic cardiomyopathY
Myocardial Infarction (MI), Sudden Cardiac Death Due to Cardiac Arrhythmia
Enrolling by invitationPhase 3
Selatogrel Outcome Study in Suspected Acute Myocardial Infarction
Acute Myocardial Infarction
RecruitingObservational study
Breisgau PHENO-HEART MI
Myocardial Infarction, STEMI
Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Cardiogenic Shock, Acute Myocardial Infarction (AMI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Emre Aslanger principal investigator
Marmara University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Infarction and Myocardial Ischemia, run by Marmara University at 1 site in Turkey (Türkiye).
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 27 Aug 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study was stopped early (reason given: Problems due to retrospective data acquisition). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mortality (time frame: One year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05705102, which also lists 5 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2024; AzTrials last refreshed its copy on 1 Nov 2026.